Sanofi to Double Flu-Vaccine Production
Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility.
Sanofi Pasteur (Lyon, France, www.sanofipasteur.com), the vaccine arm of Paris-based Sanofi Aventis, recently completed construction of its new influenza vaccine manufacturing facility. According to the company, this manufacturing plant will more than double its production capacity in the US. The new 14,000-square-foot facility, which cost $150 million to build, is expected to start functioning in late 2008 or early 2009, after the FDA licenses the facility.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
